|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 209.8 GBX | -1.29% |
|
+1.94% | +8.39% |
| Apr. 25 | Transcript : PureTech Health plc, 2023 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | PureTech touts "momentum" as grants shrivel but annual loss narrows | AN |
By Sabela Ojea
PureTech Health PLC said Friday that a product of its founded entity Vor Biopharma Inc. has been granted fast track designation by the U.S. Food and Drug Administration.
The London-listed biotechnology company said Vor Biopharma's VOR33 lead engineered stem cell is now a therapeutic candidate for the treatment of acute myeloid leukemia.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
09-10-21 0317ET
| 1st Jan change | Capi. | |
|---|---|---|
| +8.39% | 717M | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.36% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
PURETECH HEALTH PLC 
